Drug Trial Radar · NCT00095238
Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)
Last checked: Nov 19, 2026Latest source record: Apr 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,128
Actual
Start
Jun 2002
Primary completion
Jul 2008
Study completion Jul 2008
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Nov 2, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to learn if Irbesartan is superior to placebo in reducing mortality and cardiovascular morbidity in subjects with heart failure with preserved systolic function. The safety of this treatment will also be studied.
Conditions
- Congestive Heart Failure
Interventions
IrbesartanDrug
Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
PlaceboDrug
Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given TimepointsTime frame: Year 1, Year 2, Year 3, Year 4, Year 5
Locations
229 sites in 25 countries. Site status is shown where the registry gives one.
Local Institution
Birmingham, Alabama
Local Institution
Peoria, Arizona
Local Institution
Tucson, Arizona
Local Institution
Little Rock, Arkansas
Local Institution
Los Angeles, California
Local Institution
San Diego, California
Local Institution
San Francisco, California
Local Institution
Farmington, Connecticut
Local Institution
Jacksonville, Florida
Local Institution
Jacksonville Beach, Florida
Local Institution
Lake Worth, Florida
Local Institution
Tampa, Florida
Local Institution
Vero Beach, Florida
Local Institution
Chicago, Illinois
Local Institution
Peoria, Illinois
Local Institution
Jeffersonville, Indiana
Local Institution
Louisville, Kentucky
Local Institution
Chalmette, Louisiana
Local Institution
Shreveport, Louisiana
Local Institution
Auburn, Maine
Local Institution
Takoma Park, Maryland
Local Institution
Towson, Maryland
Local Institution
Boston, Massachusetts
Local Institution
Haverhill, Massachusetts
Local Institution
Natick, Massachusetts
Local Institution
Detroit, Michigan
Local Institution
Petoskey, Michigan
Local Institution
Minneapolis, Minnesota
Local Institution
St Louis, Missouri
Local Institution
Omaha, Nebraska
Local Institution
Reno, Nevada
Local Institution
Lebanon, New Hampshire
Local Institution
Elmer, New Jersey
Local Institution
Albuquerque, New Mexico
Local Institution
Albany, New York
Local Institution
East Syracuse, New York
Local Institution
Flushing, New York
Local Institution
Rochester, New York
Local Institution
The Bronx, New York
Local Institution
Troy, New York
Showing 40 of 229 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.